Literature DB >> 19941339

Construct and concurrent validation of the MG-QOL15 in the practice setting.

Ted M Burns1, C K Grouse, Mark R Conaway, Donald B Sanders.   

Abstract

Health-related quality of life (HRQOL) estimates can play an important role in patient care by providing information about the patient's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. The 15-item myasthenia gravis quality of life scale (MG-QOL15) is an HRQOL evaluative instrument specific to patients with myasthenia gravis (MG) that was designed to be easy to administer and interpret. In this multicenter study we demonstrate the construct validity of the MG-QOL15 in the practice setting. To assess the construct validity, score distributions were examined for test items in different MG patient groups that represent the clinical spectrum of the disease. For example, patients in remission more frequently scored test items as normal than did patients in other groups. Patients with lower (better) MG composite scores also more frequently scored items as normal than did patients with higher (worse) scores. There was also appropriate correlation between the MG-QOL15 and the other MG-specific scales studied. The study findings shed light on what troubles MG patients. The MG-QOL15 has construct validity in the clinical practice setting and represents an efficient and valuable tool for assessing HRQOL for patients with MG.

Entities:  

Mesh:

Year:  2010        PMID: 19941339     DOI: 10.1002/mus.21609

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

1.  Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.

Authors:  Yuriko Nagane; Hiroyuki Murai; Tomihiro Imai; Daisuke Yamamoto; Emiko Tsuda; Naoya Minami; Yasushi Suzuki; Tetsuya Kanai; Akiyuki Uzawa; Naoki Kawaguchi; Masayuki Masuda; Shingo Konno; Hidekazu Suzuki; Masashi Aoki; Kimiaki Utsugisawa
Journal:  BMJ Open       Date:  2017-02-23       Impact factor: 2.692

Review 2.  Eculizumab: A Review in Generalized Myasthenia Gravis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

3.  Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Authors:  Henning Andersen; Renato Mantegazza; Jing Jing Wang; Fanny O'Brien; Kaushik Patra; James F Howard
Journal:  Qual Life Res       Date:  2019-03-23       Impact factor: 4.147

4.  Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Authors:  Srikanth Muppidi; Kimiaki Utsugisawa; Michael Benatar; Hiroyuki Murai; Richard J Barohn; Isabel Illa; Saiju Jacob; John Vissing; Ted M Burns; John T Kissel; Richard J Nowak; Henning Andersen; Carlos Casasnovas; Jan L de Bleecker; Tuan H Vu; Renato Mantegazza; Fanny L O'Brien; Jing Jing Wang; Kenji P Fujita; James F Howard
Journal:  Muscle Nerve       Date:  2019-03-08       Impact factor: 3.217

5.  Clinical outcome measures following plasma exchange for MG exacerbation.

Authors:  Shruti M Raja; James F Howard; Vern C Juel; Janice M Massey; Manisha Chopra; Jeffrey T Guptill
Journal:  Ann Clin Transl Neurol       Date:  2019-09-27       Impact factor: 4.511

6.  Determinants of quality of life in Brazilian patients with myasthenia gravis.

Authors:  Aline Mansueto Mourão; Rodrigo Santiago Gomez; Luiz Sergio Mageste Barbosa; Denise da Silva Freitas; Elizabeth Regina Comini-Frota; Arthur Kummer; Stella Maris Aguiar Lemos; Antonio Lucio Teixeira
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

7.  'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.

Authors:  John Vissing; Saiju Jacob; Kenji P Fujita; Fanny O'Brien; James F Howard
Journal:  J Neurol       Date:  2020-03-18       Impact factor: 4.849

8.  Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.

Authors:  Deepthi Vemuri; Butchi Raju Garuda; S Gopi; T Sateesh Kumar; U Aruna Kumari
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

9.  Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Authors:  James F Howard; Richard J Nowak; Gil I Wolfe; Miriam L Freimer; Tuan H Vu; John L Hinton; Michael Benatar; Petra W Duda; James E MacDougall; Ramin Farzaneh-Far; Henry J Kaminski; Richard Barohn; Mazen Dimachkie; Mamatha Pasnoor; Constantine Farmakidis; Tina Liu; Samantha Colgan; Michael G Benatar; Tulio Bertorini; Rekha Pillai; Robert Henegar; Mark Bromberg; Summer Gibson; Teresa Janecki; Miriam Freimer; Bakri Elsheikh; Paige Matisak; Angela Genge; Amanda Guidon; William David; Ali A Habib; Veena Mathew; Tahseen Mozaffar; John L Hinton; William Hewitt; Deborah Barnett; Patricia Sullivan; Doreen Ho; James F Howard; Rebecca E Traub; Manisha Chopra; Henry J Kaminski; Radwa Aly; Elham Bayat; Mohammad Abu-Rub; Shaida Khan; Dale Lange; Shara Holzberg; Bhupendra Khatri; Emily Lindman; Tayo Olapo; Lisa M Sershon; Robert P Lisak; Evanthia Bernitsas; Kelly Jia; Rabia Malik; Tiffany D Lewis-Collins; Michael Nicolle; Richard J Nowak; Aditi Sharma; Bhaskar Roy; Joan Nye; Michael Pulley; Alan Berger; Yasmeen Shabbir; Amit Sachdev; Kimberly Patterson; Zaeem Siddiqi; Mark Sivak; Joan Bratton; George Small; Anem Kohli; Mary Fetter; Tuan Vu; Lucy Lam; Brittany Harvey; Gil I Wolfe; Nicholas Silvestri; Kara Patrick; Karen Zakalik; Petra W Duda; James MacDougall; Ramin Farzaneh-Far; Angela Pontius; Michelle Hoarty
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

10.  Understanding side effects of therapy for myasthenia gravis and their impact on daily life.

Authors:  Elizabeth Dansie Bacci; Karin S Coyne; Jiat-Ling Poon; Linda Harris; Audra N Boscoe
Journal:  BMC Neurol       Date:  2019-12-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.